X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-06-03 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.93 | -192 | 67,611 | 0% | -$563 | ||||||
2026-06-01 | GNLX | Thomas John | Dir | S - Sale | $2.98 | -10,000 | 472,784 | -2% | -$29,801 | ||||||
2026-05-11 | GNLX | Yu Yong | Chief Scientific Officer | S - Sale | $2.97 | -605 | 149,706 | 0% | -$1,798 | ||||||
2026-05-11 | GNLX | Cappello Joseph | Chief Technical Officer | S - Sale | $2.97 | -605 | 154,549 | 0% | -$1,799 | ||||||
2026-05-11 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.94 | -2,798 | 532,051 | -1% | -$8,226 | ||||||
2026-05-11 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.98 | -270 | 67,803 | 0% | -$804 | ||||||
| M | 2026-03-24 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.46 | -585 | 68,073 | -1% | -$1,437 | |||||
2026-03-24 | GNLX | Cappello Joseph | Chief Technical Officer | S - Sale | $2.42 | -906 | 155,154 | -1% | -$2,193 | ||||||
2026-03-24 | GNLX | Yu Yong | SVP, Clinical Development | S - Sale | $2.42 | -906 | 144,938 | -1% | -$2,193 | ||||||
2026-03-24 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.42 | -3,582 | 534,849 | -1% | -$8,668 | ||||||
2026-03-02 | GNLX | Thomas John | Dir | S - Sale | $2.90 | -10,000 | 482,784 | -2% | -$28,957 | ||||||
| M | 2025-08-21 | GNLX | Yu Yong | SVP, Clinical Development | S - Sale | $3.82 | -4,192 | 145,844 | -3% | -$16,032 | |||||
| M | 2025-08-21 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $3.86 | -17,182 | 538,431 | -3% | -$66,370 | |||||
| M | 2025-08-21 | GNLX | Cappello Joseph | Chief Technical Officer | S - Sale | $3.88 | -3,706 | 156,060 | -2% | -$14,361 | |||||
| M | 2025-08-21 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $3.75 | -2,332 | 68,658 | -3% | -$8,740 | |||||
2025-12-01 | GNLX | Thomas John | Dir | S - Sale | $5.00 | -10,000 | 492,784 | -2% | -$50,008 | ||||||
2025-05-12 | GNLX | Ryder Sean | GC | S - Sale | $2.92 | -4,475 | 47,621 | -9% | -$13,067 | ||||||
2025-05-12 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.92 | -10,764 | 191,447 | -5% | -$31,431 | ||||||
2025-05-12 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $2.92 | -5,579 | 47,640 | -10% | -$16,291 | ||||||
2025-05-12 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.92 | -4,737 | 52,266 | -8% | -$13,832 | ||||||
2025-05-12 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.92 | -1,259 | 34,760 | -3% | -$3,676 | ||||||
2024-12-30 | GNLX | Tyree James L | Dir | S - Sale | $2.46 | -3,460 | 45,791 | -7% | -$8,512 | ||||||
2024-12-16 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.34 | -14,315 | 37,372 | -28% | -$33,497 | ||||||
2024-12-16 | GNLX | Zak Lourie S. | CFO | S - Sale | $2.34 | -2,103 | 40,802 | -5% | -$4,921 | ||||||
2024-12-16 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.34 | -2,510 | 16,322 | -13% | -$5,873 | ||||||
2024-12-16 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.34 | -6,300 | 14,653 | -30% | -$14,742 | ||||||
| M | 2024-09-12 | GNLX | Szalay Aladar | 10% | S - Sale | $2.65 | -64,857 | 3,413,581 | -2% | -$171,678 | |||||
2024-09-11 | GNLX | Tyree James L | Dir | S - Sale | $2.60 | -1,730 | 47,521 | -4% | -$4,499 | ||||||
| M | 2024-09-09 | GNLX | Szalay Aladar | 10% | S - Sale | $2.62 | -75,143 | 3,478,438 | -2% | -$196,609 | |||||
2024-09-03 | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -42,818 | 3,553,581 | -1% | -$89,614 | ||||||
| M | 2024-08-28 | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -265,552 | 3,596,399 | -7% | -$554,411 | |||||
| M | 2024-08-23 | GNLX | Szalay Aladar | 10% | S - Sale | $2.19 | -91,630 | 3,861,951 | -2% | -$200,278 | |||||
2024-06-24 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $2.12 | -6,849 | 10,869 | -39% | -$14,520 | ||||||
2024-06-24 | GNLX | Ryder Sean | GC | S - Sale | $2.12 | -5,496 | 19,388 | -22% | -$11,652 | ||||||
2024-06-24 | GNLX | Jewett Caroline | Head of Quality | S - Sale | $2.12 | -4,961 | 16,174 | -23% | -$10,517 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |